Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index

NCT02576080 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Gastrointestinal Stromal Tumor

Interventions

DRUG: Imatinib
OTHER: Surveillance

Sponsor

Assistance Publique Hopitaux De Marseille